Naltrexone and Bupropion with Behavioral Therapy for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
This clinical trial tests the feasibility of naltrexone and bupropion with behavioral therapy for weight loss and smoking cessation in patients who are planning to undergo weight loss (bariatric) surgery. Adults that smoke and have obesity are at high risk for mortality. A subgroup of adults that smoke and have severe obesity seek bariatric surgery to improve health. These patients are required to lose weight and quit smoking, which is uniquely challenging as smoking cessation is associated with weight gain. Bariatric surgery patients that smoke may significantly benefit from a tailored intervention consisting of both medication and behavioral therapy targeting weight loss and smoking cessation. Naltrexone is a drug that blocks the action of opiates (drugs used to treat pain). It may also target reward processes that drive problematic eating behaviors, which may work as treatment for nicotine dependence and preventing weight gain after smoking cessation. Bupropion is a type of antidepressant that is also used to help people quit smoking. Giving naltrexone and bupropion with behavioral therapy may be feasible and effective for weight loss and smoking cessation for patients undergoing bariatric surgery.